The News Review:
- Earth-friendly Cherokee office gets top rating
- DATATRAK International Management To Host Conference Call on November…
- Failed AIDS vaccine may increase risk
- Study Finds New Version of QIAGEN’s HPV Test for Developing…
Earth-friendly Cherokee office gets top rating
News & bserver – Nov 8, 2007
Charity bingo events take place on Saturday nights. Leed Associates a mental health practice focusing on psychotherapy pain management and pharmaceutical clinical research consulting has expanded and now operates in the Maynard ffice Center at 1350 S. Maynard Road Suite 203 in Cary. Burt’s Bees which manufactures all-natural personal care items is addressing the disappearance of bees called colony collapse disorder by developing a campaign with co-founder Burt Shavitz to raise consumer awareness through PSA distribution online marketing and consumer sampling efforts. Burt’s Bees will also partner with the North American Pollinator Protection Campaign with research funding as well as an awareness campaign.
DATATRAK International Management To Host Conference Call on November…
earthtimes.org – Nov 8, 2007
"DATATRAK International Inc. is a worldwide technology company focused on the provision of multi-component eClinical solutions and related services for the clinical trials industry. The Company delivers a complete portfolio of software products that were created in order to accelerate clinical research data from investigative sites to clinical trial sponsors and ultimately the FDA faster and more efficiently than manual methods or loosely integrated technologies. DATATRAK’s eClinical software suite can be deployed worldwide through an ASP offering or in a licensed Enterprise Transfer model that fully empowers its clients. The DATATRAK software suite and its earlier versions have successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 59 countries. DATATRAK International Inc. ‘s product suite has been utilized in some aspect of the clinical development of 17 drugs and devices that have received regulatory approval from either the United States Food and Drug Administration or counterpart European bodies.
Failed AIDS vaccine may increase risk
NEWS.com.au – Nov 8, 2007
Further analysis showed that those who received the vaccine had a higher rate of infection than those who received a placebo said US pharmaceutical giant Merck which helped develop the vaccine. The study volunteers who received the vaccine were being advised of their potentially increased susceptibility Merck said. "We are analysing the data to try to determine if the results are due to immune responses induced by the vaccine differences in study populations or some other biological phenomenon we don’t yet understand or simply due to chance" said Keith Gottesdiener vice president of Merck’s vaccine and infectious disease clinical research. "It will take some time before we understand why the vaccine did not work and why there was a trend toward more cases of infection in volunteers who received the vaccine" he said. The experimental vaccine did not cause infection Merck said. It was a modified cold virus used to deliver three synthetically produced HIV genes in the hope of stimulating a response from the immune system. The randomised double-blind trials were conducted in various sites in Australia North America South America the Caribbean and South Africa.
Study Finds New Version of QIAGEN’s HPV Test for Developing…
Free with registration – PR Newswire – AccessMyLibrary.com – Nov 8, 2007
An economic modeling analysis found that the “FastHPV” test which is being developed specifically for cervical cancer screening in countries such as China and India could reduce the incidence of cervical cancer by as much as 56 percent if given just three times over a woman’s life and combined with appropriate treatment. In addition a clinical research study concluded that the FastHPV test produces rapid accurate results yet is also simple to run requires minimal infrastructure and will be affordable for public-health programs in those countries. FastHPV — a molecular test for cancer-causing types of HPV (human papillomavirus) — is under development by QIAGEN N. (Nasdaq: QGEN; Frankfurt Prime Standard: QIA) in partnership with PATH. The test — on track to be submitted for its first regulatory approvals in countries like China and India in 2008 — is specially designed to allow women in areas with scarce healthcare resources to benefit from the advanced technology of HPV testing.
